Top Markets
Coin of the day
Cypherpunk Technologies Inc. Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc.

CYPH
Peringkat dalam Saham #19166
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the... Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development. Cypherpunk has established an agreement with Adimab, LLC and BeiGene, Ltd., granting it options and licenses to advance and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Founded in 2011, the company operates from Cambridge, Massachusetts, and was formerly known as Leap Therapeutics, Inc. until its renaming in November 2025.
Harga Saham
$1.62
Terakhir disinkronkan: 2026-08-25
Kapitalisasi Pasar
$172.47M
Perubahan (1 hari)
-3.57%
Perubahan (1 tahun)
446.74%
Negara
US
Perdagangan Cypherpunk Technologies Inc. (CYPH)

Kategori

Jumlah saham beredar untuk Cypherpunk Technologies Inc. (CYPH)
Jumlah saham beredar per August 2026: 0
Menurut laporan keuangan terbaru dan harga saham Cypherpunk Technologies Inc., jumlah saham beredar saat ini adalah 0. Pada akhir August 2026, perusahaan memiliki 0 saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Cypherpunk Technologies Inc. (CYPH) dari 2026 hingga 2026
Saham beredar pada akhir setiap tahun
Tahun Saham Beredar Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Saham beredar untuk perusahaan serupa atau pesaing
Perusahaan Saham Beredar Perbedaan Negara
253.90M -
US
62.19M -
NL
396.00M -
US
478.91M -
AU
- -
CH